Interventional Cardiology Fellows
Cameron Dowling, MBBS, PhD
Dr. Dowling is an Australian cardiology fellow currently undertaking interventional training at Stanford. He undertook medical training at the University of Adelaide, South Australia before completing his general cardiology fellowship at St Vincent’s Hospital, Sydney. Dr Dowling then completed a PhD at the University of London, where he developed, validated, and described the first‐in‐human experience of a computer model of TAVR in bicuspid aortic valve. He then undertook coronary and structural interventional cardiology training at MonashHeart, Melbourne. Dr Dowling is an emerging opinion leader in the field of TAVR and is frequently invited to speak at international conferences. He is the recipient of numerous national and international research awards, including the BCIS Young Investigator Award and the CRT Young Leadership Award. He is the principal investigator on several trials evaluating the application of computer modelling to TAVR procedures. Dr Dowling wishes to pursue a clinical and academic career in coronary and structural intervention, with an interest in computational modelling and investigational devices. When outside of the cath lab, he enjoys reading, bicycle riding and piano.
Maggie Ning, MD, PharmD
Dr. Ning was born in China, but she grew up mostly in Texas. She went to the University of Texas at Austin for undergrad and received her PharmD degree at the College of Pharmacy. She received her MD degree from UT Southwestern Medical Center and moved to California for Internal Medicine residency at Stanford. Dr. Ning plans to continue her training as a cardiology fellow at Stanford. She is passionate about both cardiology and oncology and thoroughly enjoys taking care of these patient populations. Subsequently, she has completed several research projects and publications in both fields. She hopes to combine her clinical and research interests by contributing to the growth of the field of cardio-oncology. She hopes she can also use her pharmacology background to better understand the complex pharmacokinetics and pharmacodynamics involving oncology therapies and cardiotoxicity. She is particularly interested in the role of noninvasive imaging to help identify these patients that may be at risk for cardiotoxicity.